Novadaq Technologies Inc (NASDAQ:NVDQ) (TSE:NDQ) has been given an average recommendation of “Hold” by the sixteen brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, thirteen have given a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $12.00.

Several research firms recently weighed in on NVDQ. Scotiabank dropped their price target on Novadaq Technologies from $15.50 to $13.25 and set an “outperform” rating on the stock in a research report on Tuesday, June 20th. Canaccord Genuity downgraded Novadaq Technologies from a “buy” rating to a “hold” rating and set a $11.75 target price on the stock. in a report on Monday, July 10th. Stifel Nicolaus reissued a “buy” rating and issued a $10.00 target price on shares of Novadaq Technologies in a report on Friday, June 2nd. Zacks Investment Research raised Novadaq Technologies from a “sell” rating to a “hold” rating in a report on Friday, August 18th. Finally, Northland Securities reissued a “hold” rating and issued a $11.75 target price on shares of Novadaq Technologies in a report on Monday, August 14th.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/09/16/novadaq-technologies-inc-nvdq-given-average-rating-of-hold-by-analysts.html.

Several large investors have recently made changes to their positions in NVDQ. US Bancorp DE lifted its holdings in shares of Novadaq Technologies by 0.8% during the first quarter. US Bancorp DE now owns 46,899 shares of the medical research company’s stock valued at $365,000 after purchasing an additional 362 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Novadaq Technologies by 14.7% during the first quarter. Bank of New York Mellon Corp now owns 73,875 shares of the medical research company’s stock valued at $576,000 after purchasing an additional 9,454 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Novadaq Technologies by 12.9% during the first quarter. Envestnet Asset Management Inc. now owns 25,374 shares of the medical research company’s stock valued at $197,000 after purchasing an additional 2,898 shares in the last quarter. AXA lifted its holdings in shares of Novadaq Technologies by 8.2% during the first quarter. AXA now owns 1,160,732 shares of the medical research company’s stock valued at $9,042,000 after purchasing an additional 88,378 shares in the last quarter. Finally, OppenheimerFunds Inc. bought a new position in shares of Novadaq Technologies during the first quarter valued at $13,900,000. 75.38% of the stock is currently owned by hedge funds and other institutional investors.

Novadaq Technologies (NASDAQ:NVDQ) opened at 11.75 on Friday. Novadaq Technologies has a one year low of $5.84 and a one year high of $12.74. The company’s market capitalization is $679.41 million. The company has a 50 day moving average price of $11.68 and a 200-day moving average price of $9.03.

About Novadaq Technologies

NOVADAQ Technologies Inc is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed.

Analyst Recommendations for Novadaq Technologies (NASDAQ:NVDQ)

Receive News & Ratings for Novadaq Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novadaq Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.